Fc Engineered Anti-Human CD20 Therapeutic Antibody, a CDC-Enhanced Biobetter [Lot: CB20-PZ48] (CAT#: BioBet-C048ZP) Datasheet

MS4A1

membrane spanning 4-domains A1

This gene encodes a member of the membranespanning 4A gene family. Members of this nascent protein family are characterized by common structural features and similar intron/exon splice boundaries and display unique expression patterns among hematopoietic cells and nonlymphoid tissues. This gene encodes a Blymphocyte surface molecule which plays a role in the development and differentiation of Bcells into plasma cells. This family member is localized to 11q12, among a cluster of family members. Alternative splicing of this gene results in two transcript variants which encode the same protein.

B1, S7, Bp35, CD20, CVID5, MS4A2, LEU-16,

Protein Based Therapies
Monoclonal antibody (mAb)

Humanized IgG1

Ocrelizumab, trade name Ocrvus, is a humanized anti-CD20 monoclonal antibody. It targets the CD20 marker on B lymphocytes and is therefore an immunosuppressive drug. It was developed by Genentech / Roche and was approved by the FDA in March 2017 for the treatment of multiple sclerosis.

Multiple Sclerosis, Primary Progressive
Relapsing Multiple Sclerosis (RMS)

Ocrelizumab is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B lymphocytes that express the CD20 antigen. B lymphocytes are known to promote the pathogenesis of MS by activating pro-inflammatory T cells and secreting pro-inflammatory cytokines. Ocrelizumab promotes cytotoxicity of antibody-dependent cells and complement-mediated cell lysis by binding to CD20-expressing B lymphocytes. Ocrelizumab may induce antibody-dependent cytotoxicity, involving macrophages, natural killer cells, and cytotoxic T cells that work together to cause cell death.

Multiple Sclerosis, Primary Progressive
Relapsing Multiple Sclerosis (RMS)